Literature DB >> 6423061

Clinicopathological observations on metastasis in man studied in patients treated with peritoneovenous shunts.

D Tarin, J E Price, M G Kettlewell, R G Souter, A C Vass, B Crossley.   

Abstract

Fourteen patients with inoperable cancer treated with peritoneovenous shunts for malignant ascites were studied post mortem. Clinical observations and findings at necropsy indicated that peritoneovenous shunting does not result in the establishment of clinically important haematogenous metastases and that metastases do not necessarily develop even when large numbers of viable tumour cells regularly enter the blood. Peritoneovenous shunting provides a unique opportunity for collecting data on the spread of tumours in man.

Entities:  

Mesh：

Year:  1984        PMID： 6423061      PMCID： PMC1444638          DOI： 10.1136/bmj.288.6419.749

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


  10 in total

1.  Further experience with peritoneo-venous shunt for ascites.

Authors:  H H LeVeen; S Wapnick; S Grosberg; M J Kinney
Journal:  Ann Surg       Date:  1976-11       Impact factor: 12.969

2.  Dissemination of tumour cells via LeVeen shunt.

Authors:  B Maat; J Oosterlee; J A Spaas; H White; F B Lammes
Journal:  Lancet       Date:  1979-05-05       Impact factor: 79.321

3.  The treatment of resistant malignant ascites by insertion of a peritoneo-atrial Holter valve.

Authors:  A V Pollock
Journal:  Br J Surg       Date:  1975-02       Impact factor: 6.939

4.  Peritoneovenous shunts in the management of malignant ascites.

Authors:  R G Souter; D Tarin; M G Kettlewell
Journal:  Br J Surg       Date:  1983-08       Impact factor: 6.939

5.  Fatal pulmonary tumor embolization following peritoneovenous shunting for malignant ascites.

Authors:  R R Smith; S S Sternberg; M A Paglia; R B Golbey
Journal:  J Surg Oncol       Date:  1981       Impact factor: 3.454

6.  Absence of metastatic sequelae during long-term treatment of malignant ascites by peritoneo-venous shunting. A clinico-pathological report.

Authors:  D Tarin; A C Vass; M G Kettlewell; J E Price
Journal:  Invasion Metastasis       Date:  1984

7.  Peritoneovenous shunt for palliation of malignant ascites.

Authors:  R Qazi; E D Savlov
Journal:  Cancer       Date:  1982-02-01       Impact factor: 6.860

8.  Selection of patients with malignant ascites for a peritoneovenous shunt.

Authors:  D K Cheung; J H Raaf
Journal:  Cancer       Date:  1982-09-15       Impact factor: 6.860

9.  Peritoneovenous shunting in the management of malignant ascites.

Authors:  A K Straus; D L Roseman; T M Shapiro
Journal:  Arch Surg       Date:  1979-04

10.  Management of malignant ascites with peritoneovenous shunting.

Authors:  R B Reinhold; J J Lokich; J Tomashefski; P Costello
Journal:  Am J Surg       Date:  1983-04       Impact factor: 2.565
  10 in total
  13 in total

1.  Pre-clinical mouse models of human prostate cancer and their utility in drug discovery.

Authors:  Serk In Park; Sun Jin Kim; Laurie K McCauley; Gary E Gallick
Journal:  Curr Protoc Pharmacol       Date:  2010-12

2.  Transcriptomic signature of cell lines isolated from canine mammary adenocarcinoma metastases to lungs.

Authors:  M Król; J Polańska; K M Pawłowski; P Turowski; J Skierski; A Majewska; M Ugorski; R E Morty; T Motyl
Journal:  J Appl Genet       Date:  2010       Impact factor: 3.240

3.  Roles of bone marrow cells in skeletal metastases: no longer bystanders.

Authors:  Serk In Park; Fabiana N Soki; Laurie K McCauley
Journal:  Cancer Microenviron       Date:  2011-08-02

4.  Orthotopic implantation is essential for the selection, growth and metastasis of human renal cell cancer in nude mice [corrected].

Authors:  I J Fidler; S Naito; S Pathak
Journal:  Cancer Metastasis Rev       Date:  1990-09       Impact factor: 9.264

5.  Pleuroperitoneal shunt for recurrent malignant pleural effusions.

Authors:  V Tsang; H C Fernando; P Goldstraw
Journal:  Thorax       Date:  1990-05       Impact factor: 9.139

6.  Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors.

Authors:  Andy J Minn; Yibin Kang; Inna Serganova; Gaorav P Gupta; Dilip D Giri; Mikhail Doubrovin; Vladimir Ponomarev; William L Gerald; Ronald Blasberg; Joan Massagué
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

Review 7.  Peritoneal Metastases in Colorectal Cancer: Biology and Barriers.

Authors:  Lai Xue; Neil H Hyman; Kiran K Turaga; Oliver S Eng
Journal:  J Gastrointest Surg       Date:  2019-11-19       Impact factor: 3.452

Review 8.  The tumor cell-host organ interface in the early onset of metastatic organ colonisation.

Authors:  Peter Gassmann; Joerg Haier
Journal:  Clin Exp Metastasis       Date:  2007-12-05       Impact factor: 5.150

Review 9.  Predicting the sites of metastases.

Authors:  Brian Z Ring; Douglas T Ross
Journal:  Genome Biol       Date:  2005-12-02       Impact factor: 13.583

Review 10.  Management of ascites due to gastrointestinal malignancy.

Authors:  Muhammad W Saif; Imran A P Siddiqui; Muhammad A Sohail
Journal:  Ann Saudi Med       Date:  2009 Sep-Oct       Impact factor: 1.526
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.